Teva Pharma Industries Ltd ADR (TEVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Teva Pharma Industries Ltd ADR stock (TEVA) is currently trading at $29.46. Teva Pharma Industries Ltd ADR PE ratio is 24.08. Teva Pharma Industries Ltd ADR PS ratio (Price-to-Sales) is 1.97. Analyst consensus price target for TEVA is $38.09. WallStSmart rates TEVA as Moderate Buy.
- TEVA PE ratio analysis and historical PE chart
- TEVA PS ratio (Price-to-Sales) history and trend
- TEVA intrinsic value — DCF, Graham Number, EPV models
- TEVA stock price prediction 2025 2026 2027 2028 2029 2030
- TEVA fair value vs current price
- TEVA insider transactions and insider buying
- Is TEVA undervalued or overvalued?
- Teva Pharma Industries Ltd ADR financial analysis — revenue, earnings, cash flow
- TEVA Piotroski F-Score and Altman Z-Score
- TEVA analyst price target and Smart Rating
Teva Pharma Industries Ltd ADR
📊 No data available
Try selecting a different time range
TEVA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Teva Pharma Industries Ltd ADR (TEVA)
TEVA trades at a significant discount to its Graham intrinsic value of $56.63, offering a 39% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Teva Pharma Industries Ltd ADR (TEVA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Overall metrics suggest strong investment potential with favorable risk/reward.
Teva Pharma Industries Ltd ADR (TEVA) Key Strengths (7)
Earnings per share surging 40.00% year-over-year
Large-cap company with substantial market presence
Every $100 of equity generates $21 in profit
Good growth relative to its price
Strong operational efficiency: $27 kept per $100 revenue
Paying $1.97 for every $1 of annual revenue
60.28% held by institutions, strong professional interest
Supporting Valuation Data
Teva Pharma Industries Ltd ADR (TEVA) Areas to Watch (3)
Premium pricing at 4.2x book value
Thin profit margins with limited profitability
Solid revenue growth at 11.40% per year
Teva Pharma Industries Ltd ADR (TEVA) Detailed Analysis Report
Overall Assessment
This company scores 73/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 7 register as strengths (avg 8.6/10) while 3 fall into concern territory (avg 4.7/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on EPS Growth, Market Cap, Return on Equity. Valuation metrics including PEG Ratio (1.43), Price/Sales (1.97) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 20.80%, Operating Margin at 27.30%. Growth metrics are encouraging with EPS Growth at 40.00%.
The Bear Case
The primary concerns are Price/Book, Profit Margin, Revenue Growth. Some valuation metrics including Price/Book (4.23) suggest expensive pricing. Growth concerns include Revenue Growth at 11.40%, which may limit upside. Profitability pressure is visible in Profit Margin at 8.17%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 20.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 11.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of EPS Growth and Market Cap makes a compelling case at current levels. The key risk is Price/Book, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TEVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TEVA's Price-to-Sales ratio of 1.97x sits near its historical average of 2.06x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 14% below its historical high of 2.29x set in Mar 2026, and 1% above its historical low of 1.94x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.3x as trailing revenue scaled faster than the stock price.
Compare TEVA with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Teva Pharma Industries Ltd ADR (TEVA) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Teva Pharma Industries Ltd ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 17.3B with 11% growth year-over-year. Profit margins are thin at 8.2%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 20.8% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 1.0B in free cash flow and 1.2B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Teva Pharma Industries Ltd ADR push profit margins above 15% as the business scales?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Teva Pharma Industries Ltd ADR.
Bottom Line
Teva Pharma Industries Ltd ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(117 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SABAG, MARK See "Remarks" | Sell | -62,102 |
| Insider | Type | Shares |
|---|---|---|
KALIF, ELIYAHU SHARON EVP, Chief Financial Officer | Sell | -345,810 |
Data sourced from SEC Form 4 filings
Last updated: 1:30:24 PM
About Teva Pharma Industries Ltd ADR(TEVA)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.